A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
=== Explosives manufacture === Oleum is used in the manufacture of many explosives with the notable exception of nitrocellulose. (In modern manufacturing of nitrocellulose, the H2SO4 concentration is often adjusted using oleum.) The chemical requirements for explosives manufacture often require anhydrous mixtures containing nitric acid and sulfuric acid. Ordinary commercial grade nitric acid consists of the constant boiling azeotrope of nitric acid and water, and contains 68% nitric acid. Mixtures of ordinary nitric acid in sulfuric acid therefore contain substantial amounts of water and are unsuitable for processes such as those that occur in the manufacture of trinitrotoluene. The synthesis of RDX and certain other explosives does not require oleum. Anhydrous nitric acid, referred to as white fuming nitric acid, can be used to prepare water-free nitration mixtures, and this method is used in laboratory scale operations where the cost of material is not of primary importance. Fuming nitric acid is hazardous to handle and transport, because it is extremely corrosive and volatile. For industrial use, such strong nitration mixtures are prepared by mixing oleum with ordinary commercial nitric acid so that the free sulfur trioxide in the oleum consumes the water in the nitric acid.
=== Stoichiometry === Different stoichiometric ratios of reagents can result in different ratios of products formed. On the industrial scale, adding a large amount of reagent A to reagent B may take time. During this, the reagent A that is added is exposed to a much higher stoichiometric amount of reagent B until it is all added, and this imbalance can lead to reagent A prematurely reacting, and subsequent products to also react with the huge excess of reagent B.
=== Research articles === Ifa, Demian R; Eberlin, Livia S (January 1, 2016), "Ambient Ionization Mass Spectrometry for Cancer Diagnosis and Surgical Margin Evaluation", Clinical Chemistry, 62 (1), Oxford University Press (OUP): 111–123, doi:10.1373/clinchem.2014.237172, ISSN 0009-9147, PMC 5315420, PMID 26555455 Sans, Marta; Gharpure, Kshipra; Tibshirani, Robert; Zhang, Jialing; Liang, Li; Liu, Jinsong; Young, Jonathan H.; Dood, Robert L.; Sood, Anil K.; Eberlin, Livia S. (May 31, 2017), "Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging", Cancer Research, 77 (11), American Association for Cancer Research (AACR): 2903–2913, doi:10.1158/0008-5472.can-16-3044, ISSN 0008-5472, PMC 5750373, PMID 28416487 Santagata, Sandro; Eberlin, Livia S.; Norton, Isaiah; Calligaris, David; Feldman, Daniel R.; Ide, Jennifer L.; Liu, Xiaohui; Wiley, Joshua S.; Vestal, Matthew L.; Ramkissoon, Shakti H.; Orringer, Daniel A.; Gill, Kristen K.; Dunn, Ian F.; Dias-Santagata, Dora; Ligon, Keith L.; Jolesz, Ferenc A.; Golby, Alexandra J.; Cooks, R. Graham; Agar, Nathalie Y. R. (June 30, 2014), "Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery", Proceedings of the National Academy of Sciences, 111 (30): 11121–11126, Bibcode:2014PNAS..11111121S, doi:10.1073/pnas.1404724111, ISSN 0027-8424, PMC 4121790, PMID 24982150 Correa, Deleon N.; Santos, Jandyson M.; Eberlin, Livia S.; Eberlin, Marcos N.; Teunissen, Sebastiaan F.
Sources: en.wikipedia.org
A spider web, spiderweb, spider's web, cobweb or even just web (from the Middle English coppeweb) is a structure created by a spider out of proteinaceous spider silk extruded from its spinnerets, generally meant to catch its prey. Spider webs have existed for at least 100 million years, as witnessed in a rare find of Early Cretaceous amber from Sussex, in southern England. Many spiders build webs specifically to trap and catch insects to eat. However, not all spiders catch their prey in webs, and some do not build webs at all. The term "spider web" is typically used to refer to a web that is apparently still in use (i.e., clean), whereas "cobweb" refers to a seemingly abandoned (i.e., dusty) web. The word "cobweb" is also used by biologists to describe the tangled three-dimensional web of some spiders of the family Theridiidae. While this large family is known as the cobweb spiders, they actually have a range of different webs. Other names for this spider family include tangle-web spiders and comb-footed spiders.
=== Length === A chain loop must be of an appropriate length in order to run safely. This is described by the number of drive links. This number is determined by the length and type of bar, the sprocket size and the overall configuration of the saw. For replacement purposes, simply count the drive links on the old chain.
=== Partial drying === To achieve 0.6-0.84 water activity in food products, partial drying is employed for raw food that naturally have a high amount of humectants such as raisins, apricots, prunes and sultanas. Humectants are solutes (such as sugar or salt) that immobilize water in food. The drying process removes free water, and the humectants in the product bind the rest of the water, not allowing it to be utilized for chemical reactions or for microbial use.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。